Vifor Pharma to acquire Sanifit, supported, among other investors, by Ysios Capital, Caixa Capital Risc, Columbus Venture Partners and Alta Life Sciences

by Caixa Capital Risc

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Mediterrania Capital Partners completes ...

by Mediterrania Capital Partners

Over the tenure of MC III’s investment, TGCC has not only achieved f...

Photos Stream